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Abstract
Oncogenic secretory clusterin (sCLU) is a stress-induced molecular chaperone that con-
fers proliferative and survival advantages to hepatocellular carcinoma (HCC), plays a 
crucial role in cell proliferation, multiple drug resistance, metastasis, and tumor progres-
sion. However, the targeted effects and molecular mechanisms of sCLU for malignant 
tumor are still unknown. This chapter aims to review some progression of oncogenic 
sCLU as a promising therapeutic target for HCC. An  English-language  literature  search  
was  conducted  using  bibliographic databases on some valuable articles in focused 
review questions to analyze the interventions and findings of included studies using a 
conceptual framework. The positive rate of hepatic sCLU expression in cancerous tis-
sues was significantly higher more than that in their surrounding non-cancerous ones 
at gene transcription level or at protein level, with increasing according to tumor-node-
metastasis (TNM) staging. Abnormal expression of oncogenic sCLU associated with poor 
differentiation degree and TNM stage of HCC also has been considered as a valuable 
diagnostic or independent prognostic biomarker for HCC. Furthermore, silencing sCLU 
at mRNA level by specific shRNA or inhibition by OGX-011 suppressed the colony for-
mation and proliferation of tumor cells with apoptosis increasing, cell cycle arrested, 
alterations of cell migration and invasion behaviors, decreasing phosphorylation level 
of Akt and GSK-3β in vitro, and significantly suppressing the xenograft tumor growth 
with decreasing expression of β-catenin, p-GSK3β, and cyclinD1 in vivo. The oncogenic 
sCLU expression was closely associated with tumor progression, and it should be a novel 
potential molecular-targeted therapy for HCC.
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1. Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide 
[1]. Growing understanding of the multiple pathogenic factors including hepatitis B or C 
virus (HBV or HCV) infection, toxic, lipid accumulation, aflatoxin B1 intake, and so on with 
complex molecular mechanisms underlying HCC reveal that hepatocarcinogenesis is a mul-
tistep process including lots of activated or suppressed oncogenes or anticancer genes [2–4]. 
Some techniques for HCC therapy have experienced great progress. However, the prognosis 
of HCC patients is still very poor due to the high rates of tumor recurrence and metastasis. 
Effective therapy of HCC is dependent on early specific diagnosis, therefore, to provide opti-
mal treatment for patients, more precise and effective markers are urgently needed in all 
phases of management from early detection to staging, treatment monitoring, and prognosis 
[5–7]. Numerous studies have shown the clinical utility of novel blood-based markers, such 
as circulating tumor cells, key signal molecules, long non-coding RNA, and microRNA with 
great potential for HCC [8, 9].
Molecular chaperones are proteins that response to cellular stresses including genotoxic 
agents, nutrient starvation, and heat shock, with cellular stresses-induced protein misfold-
ing, aggregation, and denaturation [10, 11]. To date, only few specific markers such as hepa-
toma-specific γ-glutamyl transferase [12, 13], oncofetal antigen glypican-3 (GPC-3) [14, 15], 
hepatoma-specific alpha-fetoprotein (HS-AFP or AFP-L3) [16], member 3a of Wingless-type 
MMTV integration site family (Wnt3a) [17, 18], and molecular chaperones like heat shock 
proteins (Hsp27 or Hsp90) [19] and clusterin have been developed as valuable biomark-
ers for primary hepatocellular carcinoma (PHC) diagnosis and surveillance. The clusterin 
(CLU) that was first detected in HCC tissues by Tobe et al., who found that SP40-40 gene in 
hepatoma cells was located in human chromosome 8, also designated as apolipoprotein J 
(APOJ), SP-40, sulfated glycoprotein 2 (SGP2), and testosterone-repressed prostate message 
2 (TRPM2) [20]. Following the detection of their complete cDNA cloning, sequencing and 
comparison, secretory CLU (sCLU) is found to be the mature isoform of cytoplasm endo-
plasmic reticulum (ER)-Golgi CLU, which is over-expressed in a wide variety of tumors 
with oncogenicity [21, 22]. Recently, the mechanisms of abnormal sCLU expression and its 
targeted effects for HCC have been explored [23, 24]. This article summarizes some progres-
sion of sCLU as a promising target for HCC gene therapy.
2. Gene structure and functions of sCLU
Human CLU gene is a single-copy gene on chromosome 8p21-p12 including 9 exons and 8 
introns, encoding an mRNA of 2877 bp and translating to a polypeptide with 449 amino acids 
(a.a.) [25]. The secretory glycoprotein (1st a.a.) is a signal sequence of hydrophobic leader, and 
targets the ER protein. CLU gene encodes two isoforms with distinct functions as a result of 
alternative splicing and post-translational modifications: cytoplasm sCLU (75–80 kDa) and 
nuclear CLU (nCLU, 55 kDa), which is mainly located in the nucleus. The sCLU molecule is a 
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highly conserved heterodimeric disulfide-linked 449 amino acid polypeptide that represents 
the major product of CLU gene. The ER-Golgi sCLU is considered to influence immune regu-
lation, transformation, tissue remodeling, lipid transport, membrane recycling, complements 
cascade, DNA repair, cell adhesion, and cell-cell interactions, indicated that sCLU is widely 
distributed in tissues and body fluids involved in various physiological processes [11, 26, 27].
Multiple reports have shown that the cytoplasm sCLU is cytoprotective and anti-apoptotic 
[28, 29], whereas nCLU protein is proapoptotic. Abnormal oncogenic sCLU expression was 
reported to correlate closely with HCC progression, such as inducing epithelial-mesenchymal 
transition (EMT) [30], formation of multiple drug resistance (MDR) [31], distal metastasis 
of tumor cells, and malignant transformation of hepatocytes, interaction with oncogenes or 
suppressor genes, and related signal pathways (Figure 1) [32, 33]. Because of ischemic or 
hypoxic microenvironment existence in cancerous tissues, the sCLU are often adaptively 
over-expressed and closely related with increased tumorigenicity, metastatic potential, and 
MDR to chemotherapy. As a stress-induced chaperone that inhibits protein misfolding and 
aggregation in a manner similar to small heat shock proteins (HSPs) [34, 35], its promoter 
Figure 1. Potential mechanisms of hepatic sCLU in hepatocellular carcinoma. Cyto C, cytochrome c; ER, endoplasmic 
reticulum; Gene Reg., gene regulation; HIF-1α, hypoxia inducible factor-1α; IGF, insulin-like factor; MDR, multiple drug 
resistance; MMP, matrix metalloproteinase; nCLU, nuclear clusterin; NF-κB, nuclear factor-κB; PKC, protein kinase C; 
PI3K, phosphatidylinositol 3-kinase; Scr, sarcoma gene; sCLU, secretory clusterin.
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region contains an element recognized by heat shock factor 1 (HSF-1) [36]. Cytoplasm sCLU-
inhibited apoptosis by interacting with activated Bax, and protects HCC cells from ER stress-
induced apoptosis through a physical interaction with glucose-regulated prptein78 (GRP78) 
[29, 37].
Hepatic sCLU has been confirmed that it was physically associated with eukaryotic transla-
tion initiation factor 3 subunit I (EIF3I), and might protect EIF3I protein from degradation. A 
positive correlation was founded between sCLU and EIF3I, and both of their functions might 
be as a cooperative unit in HCC. The levels of sCLU and EIF3I expression were investigated 
in HCC using tissue microarray (TMA) and the patients with high EIF3I level exhibited poor 
prognosis. After silenced EIF3I, Akt phosphorylation was significantly inhibited. The EIF3I-
Akt complex could prevent PP2A-mediated dephosphorylation, which in turn led to a con-
stitutive Akt signal activation, suggesting that the CLU-EIF3I complex might prevent EIF3I 
degradation, and then contribute to Akt upregulation [33, 38].
3. Biological behaviors of sCLU expression in cancerous tissues
Although great efforts have been made to explore molecular mechanism of HCC invasion and 
metastasis in the past decade [39–41], the mechanism of HCC remains incompletely under-
stood. The alterations of sCLU expression at messenger RNA (mRNA) or protein level were 
investigated in HCC- and their non-tumorous tissues (NT) with self-control [42]. The overall 
level of sCLU mRNA in the HCC group was 75% up-regulated, 7.5% down-regulated, and 
17.5% non-changed. Although no significant difference of the sCLU mRNA level at staging I 
was found between NT and HCC, they were drastically up-regulated expression from stag-
ing II to IV. The staining of sCLU mainly presented in the cytoplasm at protein level in HCC 
and their NT tissues were analyzed by tissue microarray (TMA) with immunohistochemistry 
(IHC). Its incidence in the HCC group (73.3%), with 37.5, 68 and 88.9% at staging I, II and 
III & IV, was significantly higher than that in the NT group (23.3%), respectively. The levels 
of sCLU protein consistent with their mRNA expression were gradually upregulation with 
increasing HCC staging [42, 43], indicated that high sCLU should be a valuable biomarker to 
distinguish malignant from benign liver nodular lesions [44].
The sCLU as a functional homolog of HSPs is a stress-induced chaperone that confers prolif-
erative and closely associates with poor prognosis of HCC. Recurrence and metastasis are the 
most causes of poor prognosis of HCC. Clinicopathological features of sCLU revealed that 
its high expression was significantly linked to poor differentiation and advanced TNM stage 
[45]. There was a trend toward a poorer overall survival in HCC with high sCLU expression. 
Besides, survival time of HCC with high TNM stage was significantly shorter than that of 
cases with low stage. Moreover, in the subset of HCC patients with III and IV stage, high 
sCLU expression was prone to result in a shorter survival time (Table 1). There is a closely 
positive correlation between abnormal sCLU expression and HCC. High sCLU expression has 
more invasive phenotype for HCC [46]. The upregulation of sCLU is associated with HCC 
progression by contributing to angiogenesis, chemoresistance, cells survival, and metastasis. 
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Growing evidences showed that sCLU with molecular chaperones played an important role 
in MDR formation, cells proliferation, metastasis of HCC [47]. Furthermore, univariate and 
multivariate analyses indicated that sCLU might be an independent prognostic indicator, in 
line with the factor of lymph node metastasis.
4. Circulating sCLU as diagnostic marker
The observations were in accordance with the early literature showing that upregula-
tion of sCLU-positive expression might be associated with poor clinical outcome in HCC 
Group n Pos. n (%) χ2 value P value
AFP (μg /L) ≤50 37 31 (83.78) 1.733 0.118
>50 38 27 (71.05)
Portal vein invasion With 7 6 (85.71) 0.309 0.578
Without 68 52 (76.47)
HBsAg Negative 46 36 (78.26) 0.058 0.809
Positive 29 22 (75.86)
Tumor size ≤5 cm 45 33 (73.33) 1.027 0.311
>5 cm 30 25 (83.33)
Liver cirrhosis With 57 45 (78.95) 0.353 0.552
Without 18 13 (72.22)
Lymph node metastasis With 23 22 (95.65) 6.351 0.012*
Without 52 36 (69.23)
Differentiation Well & moderate 58 43 (74.14) 1.491 0.222
Poor 17 15 (88.24)
Gross classification Unifocal 62 46 (74.19) 1.744 0.187
Multifocal 13 12 (92.31)
TNM I & II 45 30 (66.67) 7.683 0.021*
III & IV 30 28 (93.33)
Child degree A 44 30 (68.18) 5.086 0.024*
B&C 31 29 (90.32)
5 years’ survival No 51 43 (84.31) 4.430 0.035*
Yes 24 15 (62.50)
Pos. n (%), positive number (%). *P<0.05
Table 1. Clinicopathological features of hepatic sCLU expression in HCC.
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patients [21, 48]. According to previous clinical studies, average serum sCLU level was sig-
nificantly higher in the HCC group more than that in any of groups with cirrhosis, chronic 
hepatitis, or healthy control (Table 2). The area under receiver operating characteristic 
(ROC) curve and diagnostic sensitivity were 0.75 and 74.7% in serum sCLU, and 0.74 and 
58.7% in serum AFP, respectively. The incidence of both combining detection rose up to 
90.7% for HCC diagnosis (Table 3). High-circulating sCLU levels were observed in HCC 
patients, consistent with a recent study using a three-step serum proteome analysis, which 
showed that serum sCLU levels in HCC were significantly higher than those in benign 
liver diseases [42].
CLU is related to reverse cholesterol transport, platelet degranulation and human immune 
response pathways [49]. Protein-protein interaction analysis and pathway assessment 
showed a closed molecular relationship between cirrhosis and HCC [50]. Serum samples 
collected from HCCLM3-R metastatic HCC tumor model at specific stages of metastasis 
(1., 3 and 6 weeks) were subjected to iTRAQ labeling followed by 2DLC-ESI-MS/MS analy-
sis. Circulating sCLU was significantly up-regulated during cancer progression and metas-
tasis. The expression of sCLU was significantly higher in metastatic HCC cells and samples 
from HCC patients. Serum sCLU was highly increased with tumor size, tumor number, 
lymph node infiltration (Table 4) [42], and showed that the ROC area under curve value 
was 0.95 in sCLU more than that (0.85) in AFP. If 128 μg/mL as a cutoff value, the sensi-
tivity or specificity of serum sCLU level for predicting HCC was 90 or 87%, respectively. 
The data indicated that circulating sCLU is a promising molecular marker of diagnosis or 
predicting metastasis for HCC [22, 51, 52].
Group n Mean ± SD Positive n (%) χ2 value P value
sCLU μg/mL
HCC 75 119.21 ± 16.67 56 (74.67)
LC 30 97.78 ± 19.06 8 (26.67)** 20.744 <0.001
CH 30 106.30 ± 19.22 12 (40.00)** 11.285 <0.001
NC 36 89.96 ± 7.27 0 (0.00)** 54.249 <0.001
AFP ng/mL
HCC 75 2177.32 ± 3757.99 44 (58.67)
LC 30 126.84 ± 244.76 10 (33.33)* 5.505 0.019
CH 30 30.27 ± 50.09 5 (16.67)** 15.188 <0.001
NC 36 7.1 ± 3.50 1 (2.78)** 31.520 <0.001
Serum sCLU values >104.0 μg/mL or AFP values >50 ng/mL were considered positive.
sCLU, secretory clusterin; LC, liver cirrhosis; CH, chronic hepatitis; NC, normal control; and AFP, α-fetoprotein.
*P < 0.05, compared with HCC group.
**P < 0.01, compared with HCC group.
Table 2. Serum sCLU or AFP levels among patients with chronic liver diseases and comparative analysis of both 
diagnostic values for HCC.
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sCLU level > 104.2 μg/mL (%) AFP level > 50 ng/mL (%) Both (%)
Sensitivity (%) 74.67 58.67 90.67
Specificity (%) 66.67 75.00 60.00
Accuracy (%) 71.11 65.93 77.03
Positive predictive value (%) 73.68 74.58 73.91
Negative predictive value (%) 67.80 59.21 83.72
AFP, α-fetoprotein; sCLU, secretory clusterin.
Table 3. Assessment diagnostic validity of serum sCLU or AFP level for HCC.
Group n Average (μg/mL) t value P value Positive, n (%) χ2 value P value
Age (years)
≤60 47 118.09 ± 16.45 0.751 0.455 33 (70.21) 1.320 0.251
>60 28 121.09 ± 17.16 23 (82.14)
AFP (μg/L)
≤50 31 120.15 ± 17.12 0.405 0.686 24 (77.42) 0.212 0.645
>50 44 118.55 ± 16.50 32 (72.73)
Portal vein invasion
With 28 119.34 ± 14.52 0.050 0.960 22 (78.57) 0.360 0.548
Without 47 119.14 ± 17.97 34 (72.34)
Tumor size
≤5 cm 34 114.63 ± 18.10 2.221 0.029a 21 (61.76) 5.473 0.019
>5 cm 41 123.00 ± 14.52 35 (85.37)
Lymph node metastasis
Without 44 114.84 ± 15.21 2.826 0.006b 29 (65.91) 4.316 0.038
With 31 125.40 ± 16.91 27 (87.10)
Differentiation
Well & moderate 57 117.43 ± 16.34 1.662 0.101 42 (73.68) 0.121 0.728
Poor 18 124.84 ± 16.90 14 (77.78)
Gross classification
Unifocal 36 114.02 ± 18.57 2.698 0.009c 23 (63.89) 4.251 0.039
Multifocal 39 124.00 ± 13.20 33 (84.62)
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5. Application prospect of targeting CLU gene
5.1. Antisense oligonucleotide (ASO) therapy
ASO is a useful technique to inhibit specific-targeted CLU genes, with a small synthetic natu-
ral nucleic acid analogue, that can complementary to CLU mRNA that induce degradation or 
inhibit translation into protein [52]. It is considered to be a potent inhibitor of sCLU expres-
sion in vitro, in vivo, and in human clinical trials, with no apparent effect on the expression 
of nCLU. Custirsen (OGX-011, 5′-CAGCAGCA GAGTCTTCATCAT-3′, 50 nM) is a novel 
2′-methoxy-ethyl-modified phosphorothioate ASO, which is a 21-nucleoside complement to 
target the translation initiation site of CLU gene exon II mRNA translation initiation site with 
one CpG motif [53]. Hence, OGX-011 plays the role of chemosensitization by influencing the 
anti-apoptotic protein sCLU instead of the proapoptotic protein nCLU. Xiu et al. have reviewed 
the current state of research on clusterin, to predict future research directions and to analyze 
the potential of the clinical application of custirsen in HCC [54]. However, the median overall 
survival of HCC cases were ms 23.4 mo in the group of the OGX-011 combining anti-cancer 
drugs (docetaxel/prednisone) and ms 22.2 mo in the other group of cases with docetaxel/pred-
nisone alone. No significant difference was found between two groups. Some potential key 
factors might contribute to its results, and still want to do more clinical trials to be ongoing [55].
5.2. Reversal MDR by specific shRNA-targeted sCLU
Resistance of tumor cells to chemotherapy continues to be a major clinical obstacle to extend the 
survival rate of patients with HCC. Recently, one of the major strategies for liver cancer is sur-
gical resection with adjuvant anti-HCC drug chemotherapy [10]. However, the HCC patients 
always tend to acquire MDR during tumor progression. MDR-related P-glycoprotein (P-gp), 
encoded by MDR1 gene is positively linked closely with chronic liver diseases, because of its 
Group n Average (μg/mL) t value P value Positive, n (%) χ2 value P value
TNM stage
I & II 31 113.93 ± 14.36 2.375 0.02d 20 (64.52) 2.878 0.09
III & IV 44 122.93 ± 17.31 36 (81.82)
Child classification
A 55 117.60 ± 14.56 1.395 0.167 40 (72.73) 0.410 0.522
B&C 20 123.63 ± 21.23 16 (80.00)
AFP, α-fetoprotein; TNM, tumor node metastasis.
aWith the tumor size ≥5 cm group.
bThe lymph node metastasis group.
cWith the multifocal group.
dWith TNM III & IV group.
Table 4. Clinicopathologic features of serum sCLU expression in HCC patients (Mean ± SD).
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drug efflux via ATP-binding cassette (ABC) family transporters, which can decrease intracellular 
concentration of anti-HCC drugs. Targeting sCLU to sensitize cancer cells to chemotherapy 
has become an attractive new strategy for cancer treatment. Previous studies found sCLU 
expressed in line with P-gp via immunohistochemical staining. The sCLU expression was 
analyzed in human hepatoma cells and chemoresistant counter-part HepG2/ADM cells. After 
transfection of shRNA-1 (5′-GTAAGTACGTC AATAAGGA-3′) into HepG2/ADM cells, the 
inhibition of CLU expression was 73.68% at mRNA level with obvious enhancement in che-
mosensitivity, and increasing apoptosis induced by doxorubicin [56]. Knockdown CLU also 
significantly decreased the drug efflux pump activity through the depression of MDR1/P-gp. 
Moreover, silencing CLU led to downregulation of β-catenin, suggesting that downregulation 
of CLU might be a key point to reverse MDR of HepG2/ADM cells [57].
5.3. Blockade-related pathway
5.3.1. PI3K/Akt/NF-κB pathway
Previous data revealed that CLU promoted cell survival through the PI3K/Akt pathway and 
induced MMP-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways [32]. CLU could 
increase p-Akt and MMP13 expression. A positive correlation between CLU expression and 
p-Akt level was observed in cohort of HCC tissues. Where CLU knockdown using OGX-
011 significantly decreased p-Akt and MMP13 levels and suppressed HCC metastasis in two 
metastatic models through inhibiting EIF3I/Akt/MMP13 signaling. The related signaling 
molecule blockade of the PI3K-Akt pathway could significantly inhibited MMP13 expres-
sion in human HepG2-CLU or HCCLM3 cells [38, 58]. Decreased level of CLU accompanied 
with downregulation of MMP13 and p-Akt was observed in tumors derived from HCCLM3-
shCLU group, revealed that p-Akt level was significantly correlated with poor prognosis and 
indicated that CLU may play a crucial role in HCC metastasis [38].
5.3.2. Wnt/β-catenin pathway
Wnt canonical pathway is often constitutively active in neoplastic cells, although, normally 
β-catenin is negatively regulated by GSK-3β that phosphorylates β-catenin to drive it for proteo-
somal degradation [30, 59]. Previous data emphasized sCLU modification after being exposed 
to Wnt⁄β-catenin inhibitor, and expressions of the crucial β-catenin and GSK-3β genes were 
detected in cases of sCLU depletion. The data indicated that sCLU suppression might lead to the 
inhibition of Wnt/β-catenin pathway in reverse. Hence, sCLU might play an important role in 
chemoresistance of HepG2/ADM cells together with Wnt/β-catenin signaling molecules [31, 56].
5.3.3. IGF-1/IGF-1R/Src/Mek/Erk pathway
Hepatic sCLU is a general genotoxic stress-induced, prosurvival gene product implicated in 
cancer [36, 37]. The regulatory signal transduction processes that control sCLU expression, 
the induction of sCLU is delayed, peaking 72 h after low doses of ionizing radiation, and is 
dependent on up-regulating IGF-1 and phosphorylation-dependent IGF-1R activation [23, 
27] that stimulates the downstream Src-Mek-Erk signal transduction cascade to ultimately 
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transactivate the early growth response-1 (Egr-1) transcription factor. Thus, the ionizing radi-
ation exposure causes stress-induced IGF-1R-Src-Mek-Erk-Egr-1 activation that regulates the 
sCLU prosurvival cascade pathway for radiation resistance in HCC therapy [60].
5.4. Suppressed HCC growth in vivo by silencing sCLU
The inhibition of sCLU gene transcription by specific shRNA-1 on effects of forming time, 
growth curve, and size of orthotopic xenograft tumors after sacrifice of the mice at the 34th day 
with injection are shown in Figure 2. The mean weight of the xenograft tumors in the shRNA-1 
group was significantly less than that of the control or NC-shRNA group, respectively. 
The curves of xenograft tumor growth indicated that tumor sizes in the shRNA-1 group with 
lower mRNA level were significantly smaller less than those of the control or NC-shRNA 
group [31, 46]. Consistently, the sCLU protein expression in the shRNA-1 group was also 
Figure 2. Inhibition of sCLU gene transcription by specific shRNA-1 on effects of forming time, growth curve and 
size of orthotopic xenograft tumors. The control, neg-shRNA, or sCLU-shRNA groups were injected with the plasmid 
contained specific shRNA-1 into nude mice. (A) The forming time of the orthotopic xenograft tumors from each group. 
(B) The growth curves of the xenograft tumors from each group. And the tumor volumes were measured at the indicated 
time point. (C) The representative photographs of the nude mice and corresponding dissected tumors from each group. 
1 and 2, the xenografts in the control group; 3 and 4, the xenografts in the neg-shRNA group; 5 and 6, the xenografts in 
the sCLU-shRNA group. The data are presented as the mean ± SD. Compared with the control group, **P < 0.01.
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lower than that in the control or the NC-shRNA group; and the sCLU staining in the control 
or NC-shRNA group was stronger than that in the shRNA-1 group by immunohistochem-
istry [46]. Specific shRNA-mediated downregulation of sCLU resulted in a reduced migra-
tory capacity in HCC cell lines, as well as a reduction in pulmonary metastasis in vivo [38]. 
Overexpression of sCLU in HepG2 cell line showed increased cell migratory ability. In addi-
tion, sCLU also plays an important role in the regulation of TGF-β1-smad3 signaling path-
way, suggested that oncogenic sCLU might promote HCC metastasis via the induction of 
EMT process and could be a promising candidate target for HCC therapy [32, 61–63].
6. Conclusions
In conclusion, the upregulation of sCLU expression at early staging of HCC is considered to 
promote tumor development, which may be related to the phosphorylation of AKT/GSK-3β. 
An increasing number of reports have provided evidence that sCLU level could be a novel 
biomarker for HCC diagnosis and prognosis, and there will be of great significance for the 
individualized treatment in HCC patients. The sCLU regulating signaling pathways could be 
critical to unraveling the solution for MDR in HCC. Therefore, silencing sCLU gene transcrip-
tion and inhibiting sCLU expression by specific Custirsen inhibition have provided a new 
mechanism insight into molecular-targeted therapy for HCC in injected- or orthotopic model, 
indicated that sCLU gene would be a potential molecular-targeted for HCC therapy. Further 
study found that sCLU contributed to HCC migration and EMT in vitro, and metastasis in 
vivo. Although additional preclinical and clinical trials are necessary to explore the sCLU role 
in HCC, targeting the oncogenic sCLU could validate the approach as a systemic therapy to 
increase chemotherapy sensitivity.
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